This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Mechanistic Insights From Clinical Findings and Immunohistochemistry

Arch Dermatol. 2001;137:953-955.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THERE HAS BEEN an explosion in the use of biologic therapeutics that target molecules and cells involved in chronic inflammatory and autoimmune diseases. These agents profoundly alter the therapeutic options for patients with chronic debilitating diseases, for which there have been virtually no new therapies for many years. These new agents have revolutionized treatments in fields that routinely deal with diseases such as rheumatology, dermatology, neurology, and gastroenterology. The new biological immunomodulators include interferons, tumor necrosis factor (TNF-) inhibitors, interleukin 1 receptor antagonist, growth factors such as granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, as well as monoclonal antibodies that interfere with B-cell and T-cell activation (anti-CD20, anti-CD40, and anti-CD25), complement protein inhibitors, and numerous other important immune-modifying agents.¹ Cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin (CTLA4-Ig), one of these agents, has been previously used to treat psoriasis. Infused intravenously, it has not been associated with adverse cutaneous reactions.²

Etanercept, the subject of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Clinical, Histological, and Immunophenotypic Characteristics of Injection Site Reactions Associated With Etanercept: A Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein
Ross Zeltser, Laticia Valle, Carol Tanck, Margaret M. Holyst, Christopher Ritchlin, and Anthony A. Gaspari
Arch Dermatol. 2001;137(7):893-899.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.
Winfield et al.
Arch Dermatol 2006;142:218-220.
ABSTRACT | FULL TEXT  

Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept
Rajakulendran and Deighton
Rheumatology (Oxford) 2004;43:1588-1589.
FULL TEXT